Share Facebook Twitter Email ZUMA-7 trial reported a significant advantage in overall survival with the delivery of salvage anti-CD19 CAR T-cell Yescarta for relapsed or refractory large B-cell lymphoma. | Westin, N Engl J med 2023 CAR T-cell
